Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06193174
Other study ID # IRB-300012182
Secondary ID HT9425-23-1-0805
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date August 1, 2025
Est. completion date August 14, 2027

Study information

Verified date January 2024
Source University of Alabama at Birmingham
Contact Norma Miller, RN
Phone 2059756169
Email ncmiller@uabmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.


Description:

C134 is a genetically engineered herpes simplex virus or "HSV" (the virus that usually causes cold sores and rarely, a severe infection of the brain). It has been known that viruses may kill tumor cells. When tumor cells are mixed with certain viruses in the laboratory, the tumor cells die. The DNA of the (HSV) virus has been modified so that tumor cells may be killed when infected by C134. The changes made to the virus (HSV) should help prevent the (C134) virus from infecting normal brain tissue. Extensive testing in both mice and monkeys has demonstrated that C134 is not able to cause HSV when injected directly into the brain. C134 may also be able to help kill tumor cells because it can prevent tumor cells from killing it more effectively than other, similar viruses can. This allows it to infect and kill more brain tumor cells. C134 has been tested in more than ten patients previously. The virus has had only two instances of known significant toxicities. In one patients with extensive disease present on both sides of the brain, the virus traveled throughout the brain and as a result, caused extensive inflammation that required treatment with an antiviral drug. The patient recovered partially, but eventually succumbed to their tumor. A second patient developed an infection of the retina (back of the eye) apparently as a result of the virus migrating to that area from the site of inoculation in the occipital lobe. Based on these findings the investigators have amended the protocol to protect future patients from these toxicities as follows: 1) The dose of the virus being administered has been lowered; 2) patients with enhancing tumor on both sides of the brain are not eligible for the trial and 3) patients with disease in the occipital lobe which has connections to the retina are not eligible for the trial Based on laboratory testing, the investigators believe multiple doses of C134 viral therapy in cases such as the patients, could potentially benefit from repeat treatment as this has been seen in preclinical studies, since the patients have received C134, the patients are thus eligible for retreatment under this protocol.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 12
Est. completion date August 14, 2027
Est. primary completion date August 14, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must have histologically or cytologically confirmed recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Prior therapy. Patients must have failed a course of external beam radiotherapy to the brain at least 4 weeks prior to enrollment. Age =18 years. Because no dosing or adverse event data are currently available on the use of C134 in patients <18 years of age, children are excluded from this study but will be eligible for future pediatric phase 1 single-agent trials. Karnofsky Performance Status =70% Life expectancy of greater than 4 weeks. Patients must have normal organ and marrow function as defined below: leukocytes >3,000/ µl absolute neutrophil count >1,500/ µl platelets >100,000/ µl total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal Creatinine within normal institutional limits OR creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. Residual lesion must be =1.0 cm in diameter as determined by MRI. The effects of C134 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the first six months after receiving C134. Because it is currently unknown if C134 can be transmitted by sexual contact, a barrier method of birth control should be employed. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately. Ability to understand and the willingness to sign a written informed consent document. Females of childbearing potential must not be pregnant; this will be confirmed by a negative serum pregnancy test within 14 days prior to starting study treatment. Steroid use is allowed as long as dose has not increased within 2 weeks of scheduled C134 administration whenever possible, the patient should be on a steroid dose that is equivalent to a dexamethasone dose of = 4mg daily at the time of treatment. Patients must have previously been treated with C134 in the Phase I dose escalation study here at UAB > 4 weeks prior and have shown evidence of either tumor progression or pseudoprogression by MRI. Exclusion Criteria: Patients who have had chemotherapy, cytotoxic therapy, immunotherapy or gene therapy within 6 weeks prior to entering the study, surgical resection within 4 weeks prior to entering the study, or have received experimental viral therapy at any time (e.g., adenovirus, retrovirus or herpesvirus* protocol). Also, those who have not recovered from adverse events due to therapeutic interventions administered more than 4 weeks earlier. Patients may not be receiving any other investigational agents (except C134 per protocol). Enhancing tumor diameter larger than 5.5 cm History of allergic reactions or CTCAE version 5.0 Grade IV toxicity attributed to C134 or compounds of similar biologic composition to C134. Tumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment. Prior history of encephalitis, multiple sclerosis, or other CNS infection. Active oral herpes lesion. Concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other medical condition that precludes surgery. Also, psychiatric illness/social situations that would limit compliance with study requirements. Required steroid increase within 2 weeks of scheduled C134 administration. When possible, the patient should be on a dexamethasone equivalent dose of = 2mg daily at the time of treatment. Known history of allergic reaction to IV contrast material that is not amenable to pre-treatment by UAB protocol. Have a pacemaker, ferro-magnetic aneurysm clips, metal infusion pumps, metal or shrapnel fragments, or certain types of stents. Received Bevacizumab (Avastin) therapy within 4 weeks of scheduled C134 administration. Excluded patient groups Pregnant women are excluded from this study because C134 is a viral oncolytic therapy with unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with C134 breastfeeding should be discontinued if the mother is treated with C134. Immune deficient, because patients with immune deficiency will be unable to mount the anticipated immune response underlying this therapeutic rationale, HIV-seropositive patients are excluded from this study. Other treatment studies for this disease that are less dependent on the patients' immune response are more appropriate for HIV-seropositive patients.

Study Design


Intervention

Drug:
C134 Re-Administration
Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure of Treatment-Emergent Adverse Events Adverse events will be monitored and any changes in status will be recorded for each patient as outlined in CTCAE v4.0 reporting requirements. baseline through month 12
Secondary Measure of Progression Free Survival Patients will receive contrast-enhanced MRI to monitor progression (changes in tumor volume or tumor enhancement assessed by the iRANO criteria). As indicated in the criteria, biopsy and/or resection may be performed in instances of uncertainty. Determination of time to progression (in months) will be recorded for each patient and median progression-free survival will be calculated for the entire cohort (Kaplan-Meier). pre-study, day 3, day 28, month 3, month 6, month 12
Secondary Measure Overall Survival Patients survival will be recorded (Kaplan-Meier) day 0, day 1, day 2, day 3, day 7, day 28, month 3, month 6, month 12
Secondary Measurement of HSV titer Detection and quantification of HSV antibody titer via ELISA, pfu/mL. pre-study, day 28, month 3, month 6, month 12
Secondary Composition of the white blood cells White blood cell subset analysis by FACS, as a percent of total white blood cell number. pre-study, day 2, day 7, day 28, month 3, month 6, month 12
Secondary Measure interferon levels Intracellular lymphocyte interferon levels will be assessed by FACS analysis ng/mL pre-study, day 2, day 7, day 28, month 3, month 6, month 12
See also
  Status Clinical Trial Phase
Recruiting NCT03657576 - Trial of C134 in Patients With Recurrent GBM Phase 1
Recruiting NCT05685004 - Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Phase 2/Phase 3
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Completed NCT02474966 - Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study Phase 2
Active, not recruiting NCT02137759 - MRSI to Predict Response to RT/TMZ ± Belinostat in GBM Phase 2
Enrolling by invitation NCT03170141 - Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme Phase 1
Recruiting NCT04842513 - Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT04869449 - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas Early Phase 1
Recruiting NCT03633552 - Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Phase 3
Not yet recruiting NCT05095441 - A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma Phase 1
Completed NCT00003456 - Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme Phase 2
Completed NCT03047473 - Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme Phase 2
Enrolling by invitation NCT05116137 - The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors N/A
Recruiting NCT05627323 - CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma Phase 1
Active, not recruiting NCT04968366 - Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery Phase 1
Suspended NCT04222309 - Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) Phase 1
Not yet recruiting NCT06186440 - Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma Phase 1/Phase 2
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)